Tags

Type your tag names separated by a space and hit enter

Effects of continuous combined conjugated estrogen/medroxyprogesterone acetate and 17beta-estadiol/norethisterone acetate on lipids and lipoproteins.
Maturitas. 2004 Jun 15; 48(2):137-46.M

Abstract

OBJECTIVES

Various estrogen/progestogen combinations used in hormonal replacement therapy (HRT) have been reported to influence lipid and lipoprotein fractions differently. This motivated a comparative study where the two continuous combined regimens most commonly used in Sweden during the 1990s have been studied regarding effects on lipid profile.

METHODS

In a 1-year prospective, double-blind study, 62 post-menopausal women were randomized to conjugated estrogen (CE), 0.625 mg, and medroxyprogesterone acetate (MPA), 5 mg, or 17beta-estradiol (E2), 2 mg, and norethisterone acetate (NETA), 1 mg. Serum concentrations of lipids and lipoproteins were measured at baseline and after 1 year of treatment.

RESULTS

Both treatment groups significantly lowered the lipoprotein(a) (Lp(a)) levels. The CE/MPA group showed no significant changes in total cholesterol (TC), high-density (HDL) and low-density lipoprotein (LDL), but a significant increase of triglyceride (TG) levels. The E2/NETA group developed a significant lowering of total cholesterol, HDL, and LDL, but no significant changes of TG levels. The magnitude of change in serum concentrations of total cholesterol, HDL and TG differed significantly between the two treatment groups.

CONCLUSIONS

Continuous combined treatment with CE/MPA and E2/NETA equally lowered Lp(a), an important risk factor for cardiovascular disease in women. Apart from this, the two treatments produced different effects on lipids and lipoproteins, findings that are more delicate to interpret.

Authors+Show Affiliations

Department of Clinical Science, Obstetrics and Gynecology, Umeå University, S-901 85, Sweden.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15172088

Citation

Odmark, Inga-Stina, et al. "Effects of Continuous Combined Conjugated Estrogen/medroxyprogesterone Acetate and 17beta-estadiol/norethisterone Acetate On Lipids and Lipoproteins." Maturitas, vol. 48, no. 2, 2004, pp. 137-46.
Odmark IS, Bäckström T, Haeger M, et al. Effects of continuous combined conjugated estrogen/medroxyprogesterone acetate and 17beta-estadiol/norethisterone acetate on lipids and lipoproteins. Maturitas. 2004;48(2):137-46.
Odmark, I. S., Bäckström, T., Haeger, M., Jonsson, B., & Bixo, M. (2004). Effects of continuous combined conjugated estrogen/medroxyprogesterone acetate and 17beta-estadiol/norethisterone acetate on lipids and lipoproteins. Maturitas, 48(2), 137-46.
Odmark IS, et al. Effects of Continuous Combined Conjugated Estrogen/medroxyprogesterone Acetate and 17beta-estadiol/norethisterone Acetate On Lipids and Lipoproteins. Maturitas. 2004 Jun 15;48(2):137-46. PubMed PMID: 15172088.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of continuous combined conjugated estrogen/medroxyprogesterone acetate and 17beta-estadiol/norethisterone acetate on lipids and lipoproteins. AU - Odmark,Inga-Stina, AU - Bäckström,Torbjörn, AU - Haeger,Magnus, AU - Jonsson,Björn, AU - Bixo,Marie, PY - 2002/12/23/received PY - 2003/07/02/revised PY - 2003/08/07/accepted PY - 2004/6/3/pubmed PY - 2004/10/8/medline PY - 2004/6/3/entrez SP - 137 EP - 46 JF - Maturitas JO - Maturitas VL - 48 IS - 2 N2 - OBJECTIVES: Various estrogen/progestogen combinations used in hormonal replacement therapy (HRT) have been reported to influence lipid and lipoprotein fractions differently. This motivated a comparative study where the two continuous combined regimens most commonly used in Sweden during the 1990s have been studied regarding effects on lipid profile. METHODS: In a 1-year prospective, double-blind study, 62 post-menopausal women were randomized to conjugated estrogen (CE), 0.625 mg, and medroxyprogesterone acetate (MPA), 5 mg, or 17beta-estradiol (E2), 2 mg, and norethisterone acetate (NETA), 1 mg. Serum concentrations of lipids and lipoproteins were measured at baseline and after 1 year of treatment. RESULTS: Both treatment groups significantly lowered the lipoprotein(a) (Lp(a)) levels. The CE/MPA group showed no significant changes in total cholesterol (TC), high-density (HDL) and low-density lipoprotein (LDL), but a significant increase of triglyceride (TG) levels. The E2/NETA group developed a significant lowering of total cholesterol, HDL, and LDL, but no significant changes of TG levels. The magnitude of change in serum concentrations of total cholesterol, HDL and TG differed significantly between the two treatment groups. CONCLUSIONS: Continuous combined treatment with CE/MPA and E2/NETA equally lowered Lp(a), an important risk factor for cardiovascular disease in women. Apart from this, the two treatments produced different effects on lipids and lipoproteins, findings that are more delicate to interpret. SN - 0378-5122 UR - https://www.unboundmedicine.com/medline/citation/15172088/Effects_of_continuous_combined_conjugated_estrogen/medroxyprogesterone_acetate_and_17beta_estadiol/norethisterone_acetate_on_lipids_and_lipoproteins_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0378512203003098 DB - PRIME DP - Unbound Medicine ER -